Simple urine test could guide kidney-protective treatment choices in type 2 diabetes
· Medical Xpressedited by Gaby Clark, reviewed by Robert Egan
Gaby Clark
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Type 2 diabetes increases the risk of chronic kidney disease, making prevention of kidney failure a key part of treatment. Newer diabetes medications, including GLP-1s and SGLT2 inhibitors, can reduce the risk of kidney disease, but previous studies have included large proportions of patients who already had signs of kidney damage, making it unclear whether the findings applied to patients without kidney damage.
A new study led by Mass General Brigham researchers found that GLP-1 agonists and SGLT2 inhibitors reduced the risk of kidney deterioration in patients with diabetes who had protein in their urine, a sign of kidney damage, before treatment. However, the researchers found little evidence of kidney benefit among patients without protein in their urine. They also showed that sulfonylureas, an older class of diabetes medication, led to faster declines in kidney function in patients with diabetes who didn't have protein in their urine. Results are published in the BMJ.
"Our study shows that we need to tailor diabetes treatment to the individual patient instead of using a one-size-fits-all approach," said corresponding author Alexander Turchin, MD, MS, of the Division of Endocrinology in the Mass General Brigham Department of Medicine. "A simple urine test could help doctors assess whether a patient may receive kidney protection from GLP-1 receptor agonists or SGLT2 inhibitors and whether sulfonylureas could pose additional risk."
Tracking kidney outcomes
The researchers analyzed medical record data from 75,455 patients with type 2 diabetes across the U.S., including 13,872 who presented with protein in their urine. They followed the patients for up to five years and compared the risk of developing chronic kidney disease among patients prescribed GLP-1s and SGLT2 inhibitors with those prescribed sulfonylureas or DPP4i. All patients had moderate cardiovascular risk and were receiving metformin as their primary diabetes medication.
Among patients with protein in their urine, GLP-1s and SGLT2 inhibitors were associated with substantially better kidney outcomes than DPP4i. However, GLP-1s and SGLT2 inhibitors did not appear to provide a significant kidney benefit in patients without protein in their urine. Among patients without protein in their urine at baseline, treatment with sulfonylureas was associated with an increased risk of kidney deterioration compared with DPP4i.
Gap for lower-risk patients
Further research is needed to identify therapies to prevent kidney disease in the large population of patients with type 2 diabetes who don't present with protein in their urine, the researchers say.
"These findings will allow us to individualize medication choices that maximally benefit the patient in front of us rather than for the hypothetical 'average person,'" said Turchin. "Patients and their doctors should discuss how to balance these different risks and benefits in their individual circumstances when choosing their type 2 diabetes medications."
Publication details
Renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors and GLP-1 receptor agonists: target trial emulation, BMJ (2026). DOI: 10.1136/bmj-2026-100574
Journal information: British Medical Journal (BMJ)
Key medical concepts
ProteinuriaGlucagon-Like Peptide-1 Receptor AgonistsSodium-Glucose Transporter 2 Inhibitors
Clinical categories
NephrologyEndocrinologyCommon illnesses & Prevention Provided by Mass General Brigham Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Simple urine test could guide kidney-protective treatment choices in type 2 diabetes (2026, September 16) retrieved 16 September 2026 from https://medicalxpress.com/news/2026-09-simple-urine-kidney-treatment-choices.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.